Cover Image

CDK4/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network

Objective:The aim of this study was to investigate the potential risk of drug-induced liver injury (DILI) caused by the CDK4/6 inhibitors (CDK4/6is abemaciclib, ribociclib, and palbociclib by comprehensively analyzing the FDA Adverse Event Reporting System (FAERS) database. Moreover, potential toxic...

Full description

Saved in:

Bibliographic Details
Main Authors:	Youjun She (Author), Zihan Guo (Author), Qing Zhai (Author), Jiyong Liu (Author), Qiong Du (Author), Zhongwei Zhang (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
by: Wensheng Liu, et al.
Published: (2023)

Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study
by: Zihan Guo, et al.
Published: (2024)

Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database
by: Zhao Li, et al.
Published: (2024)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
by: Zhiwei Cui, et al.
Published: (2023)

Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database
by: Wangyu Ye, et al.
Published: (2024)

Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database
by: Qing Wan, et al.
Published: (2022)

Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database
by: PingPing Long, et al.
Published: (2024)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
by: Meng Li, et al.
Published: (2022)

Safety profiles of doxycycline, minocycline, and tigecycline in pediatric patients: a real-world pharmacovigilance analysis based on the FAERS database
by: Yanli Qiao, et al.
Published: (2024)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
by: Zhuo Ma, et al.
Published: (2021)

Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database
by: Wan Xiong, et al.
Published: (2024)

CAR-T therapy pulmonary adverse event profile: a pharmacovigilance study based on FAERS database (2017-2023)
by: Jing Shi, et al.
Published: (2024)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
by: Jianxing Zhou, et al.
Published: (2022)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
by: Hui Zhao, et al.
Published: (2023)

Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: a retrospective, pharmacovigilance study using the FAERS database
by: Huiping Hu, et al.
Published: (2024)

Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
by: Xiang Zhou, et al.
Published: (2021)

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases
by: Qian Liu, et al.
Published: (2024)

Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database
by: Yamin Shu, et al.
Published: (2022)

Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Dan Zhao, et al.
Published: (2024)

Electrolyte Disorders Associated with Piperacillin/Tazobactam: A Pharmacovigilance Study Using the FAERS Database
by: Heenam Seo, et al.
Published: (2023)

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database
by: Fan Zou, et al.
Published: (2024)

Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database
by: Shi-Nan Wu, et al.
Published: (2024)

Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database
by: Zhiwen Fu, et al.
Published: (2024)

The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database
by: Xiaogan Wang, et al.
Published: (2024)

Subset Analysis for Screening Drug-Drug Interaction Signal Using Pharmacovigilance Database
by: Yoshihiro Noguchi, et al.
Published: (2020)

Drug-induced hearing disorders: a disproportionality analysis of the FAERS database
by: Baojian Li, et al.
Published: (2024)

Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database
by: Shangze Li, et al.
Published: (2024)

Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models
by: Zhiheng Yu, et al.
Published: (2022)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
by: Fan Zou, et al.
Published: (2023)

Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
by: Junwei Wang, et al.
Published: (2024)

Anti-multiple myeloma drug-associated taste dysfunction: An analysis of the FAERS database
by: Ayano Inoba, et al.
Published: (2016)

Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database
by: Jinhua Chen, et al.
Published: (2024)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2023)

Clinical adverse events to dexmedetomidine: a real-world drug safety study based on the FAERS database
by: Feng Liu, et al.
Published: (2024)

Heparin-induced thrombocytopenia associated with low-molecular-weight heparin: clinical feature analysis of cases and pharmacovigilance assessment of the FAERS database
by: Leping Liu, et al.
Published: (2023)

Adverse drug reaction signals mining comparison of amiodarone and dronedarone: a pharmacovigilance study based on FAERS
by: Ye Xu, et al.
Published: (2024)

A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)
by: Linlin Tang, et al.
Published: (2024)

Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
by: Hui Zhao, et al.
Published: (2023)

Antihypertensive drug-associated adverse events in osteoarthritis: a study of a large real-world sample based on the FAERS database
by: Zijian Guo, et al.
Published: (2024)

Real-World Data in Pharmacovigilance Database Provides a New Perspective for Understanding the Risk of <i>Clostridium difficile</i> Infection Associated with Antibacterial Drug Exposure
by: Dongxuan Li, et al.
Published: (2023)